

Special Issue

Updates on Heart Valve Diseases: Personalized Treatment and Management

Message from the Guest Editor

Heart valve disease represents a major health problem, and heart valve replacement is considered to be the gold standard treatment. Actually, for many patients, the vast majority of available devices are adequate, but there are some patients that may benefit more from a specific device. In elderly patients and in those deemed to be at high risk for surgery, TAVI is definitely preferred over conventional surgery. Conversely, in intermediate and low-risk patients, the choice is somehow more difficult. Preoperative risk scores, such as EuroSCORE and the STS score, may be helpful. However, the abovementioned scores only predict early outcomes. In order to optimize treatment, we have to also analyze the long-term outcome. Only in this way we can achieve patient-based treatment. To fill this gap, we invite authors to submit original and review articles that explore how a personalized patient-targeted treatment can solve, or rather not solve, heart valve disease.

Guest Editor

Dr. Chiara Tessari

Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy

Deadline for manuscript submissions

30 September 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/205304

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).